Champix cleared of increased neuropsychiatric risk

Smoking cessation practitioners have welcomed a major study showing varenicline does not increase the risk of neuropsychiatric symptoms and is safe in patients with pre-existing psychiatric conditions.

A randomised controlled trial involving 8144 smokers found that rates of moderate and severe neuropsychiatric adverse events were similar for varenicline (Champix) (1.3%), bupropion (2.2%), nicotine patches (2.5%) and placebo (2.4%) in patients with no pre-existing psychiatric conditions.

The EAGLES trial also showed no increase in severe neuropsychiatric